Moderna Needs a Post-Covid Hit. Its Cancer-Drug Spending Plan Ups the Stakes.

Moderna is shifting its strategic focus toward oncology as it seeks to move beyond its pandemic-era revenue. The biotechnology firm has announced an aggressive spending plan for cancer-drug development, aiming to diversify its pipeline and restore investor confidence. However, Wall Street remains skeptical, requiring more than just future promises to justify the company's significant capital allocation and long-term growth strategy in a highly competitive pharmaceutical market.